Current Report Filing (8-k)
July 29 2020 - 4:58PM
Edgar (US Regulatory)
0001551152
false
Common Stock, $0.01 Par Value
ABBV
0001551152
2020-07-29
2020-07-29
0001551152
us-gaap:CommonStockMember
exch:XNYS
2020-07-29
2020-07-29
0001551152
exch:XCHI
us-gaap:CommonStockMember
2020-07-29
2020-07-29
0001551152
abbv:Sec1.375SeniorNotesDue2024Member
exch:XNYS
2020-07-29
2020-07-29
0001551152
abbv:Sec0.750SeniorNotesDue2027Member
exch:XNYS
2020-07-29
2020-07-29
0001551152
abbv:Sec2.125SeniorNotesDue2028Member
exch:XNYS
2020-07-29
2020-07-29
0001551152
abbv:Sec1.250SeniorNotesDue2031Member
exch:XNYS
2020-07-29
2020-07-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): July 29, 2020
ABBVIE INC.
(Exact Name of Registrant as Specified
in its Charter)
Delaware
|
|
001-35565
|
|
32-0375147
|
(State or other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (847) 932-7900
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, $0.01 Par Value
|
|
ABBV
|
|
New York Stock Exchange
Chicago
Stock Exchange
|
1.375% Senior Notes due 2024
|
|
ABBV24
|
|
New York Stock Exchange
|
0.750% Senior Notes due 2027
|
|
ABBV27
|
|
New York Stock Exchange
|
2.125% Senior Notes due 2028
|
|
ABBV28
|
|
New York Stock Exchange
|
1.250% Senior Notes due 2031
|
|
ABBV31
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
Furnished as Exhibit
99.1 to this Current Report on Form 8-K and incorporated herein by reference is certain unaudited financial information relating
to the acquisition by AbbVie Inc. (“AbbVie”) of Allergan plc (“Allergan”), which closed on May 8, 2020.
On page 1, AbbVie provides information with respect to its historical key product revenues for each of the quarters in the year
ended December 31, 2019, the year ended December 31, 2019 as well as the quarter ended March 31, 2020. On page 2, AbbVie provides information with respect to its
comparable key product revenues for each of the quarters in the year ended December 31, 2019, the year ended December 31, 2019 as well as the quarter ended March
31, 2020, which was prepared as if the acquisition of Allergan had closed on January 1, 2019.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ABBVIE INC.
|
|
|
Date: July 29, 2020
|
By:
|
/s/ Robert A. Michael
|
|
|
Robert A. Michael
|
|
|
Executive Vice President, Chief Financial Officer
|
Common Stock, $0.01 Par Value
|
ABBV
|
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2023 to Sep 2024